NICE IDs

27/04/2026

ID3753: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

27/04/2026

ID6374: Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer

22/04/2026

ID1237: Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

22/04/2026

ID5092: Rozanolixizumab for treating antibody-positive generalised myasthenia gravis

14/04/2026

ID6388: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

10/04/2026

ID6177: Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

01/04/2026

ID6407: Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

31/03/2026

ID6496: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

25/03/2026

ID6441: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

06/03/2026

ID6477: Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer

04/03/2026

ID5071: Fezolinetant for treating vasomotor symptoms associated with the menopause

02/03/2026

ID6474: Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment

02/02/2026

ID6168: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer

30/01/2026

ID6480: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648)

26/01/2026

ID6403: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673)

22/01/2026

ID6420: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

22/01/2026

ID6485: Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)

20/01/2026

ID6235: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

20/01/2026

ID6310: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

02/01/2026

ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy